File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Management of chronic lymphocytic leukaemia
Title | Management of chronic lymphocytic leukaemia |
---|---|
Authors | |
Keywords | Combined Modality Therapy Leukemia Lymph Nodes Lymphoid Rituximab |
Issue Date | 2011 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org |
Citation | Hong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 56-62 How to Cite? |
Abstract | Chronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers that influence therapeutic decisions, as well as the development of novel therapeutic agents that improve the treatment response and survival. This review discusses the value of various prognostic markers in the management of chronic lymphocytic leukaemia and the treatment options with conventional chemotherapy and newer chemoimmunotherapy regimens. However, treatment needs to be tailored to individual patients according to the patient's general physical state, ability to tolerate treatment-related toxicity, and presence of comorbidities. To that end, an approach to formulating primary and secondary treatment decisions is also presented. © 2011 Hong Kong College of Radiologists. |
Persistent Identifier | http://hdl.handle.net/10722/163484 |
ISSN | 2023 Impact Factor: 0.2 2023 SCImago Journal Rankings: 0.127 |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, E | en_US |
dc.contributor.author | Singh Gill, H | en_US |
dc.date.accessioned | 2012-09-05T05:31:52Z | - |
dc.date.available | 2012-09-05T05:31:52Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Hong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 56-62 | en_US |
dc.identifier.issn | 2223-6619 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163484 | - |
dc.description.abstract | Chronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers that influence therapeutic decisions, as well as the development of novel therapeutic agents that improve the treatment response and survival. This review discusses the value of various prognostic markers in the management of chronic lymphocytic leukaemia and the treatment options with conventional chemotherapy and newer chemoimmunotherapy regimens. However, treatment needs to be tailored to individual patients according to the patient's general physical state, ability to tolerate treatment-related toxicity, and presence of comorbidities. To that end, an approach to formulating primary and secondary treatment decisions is also presented. © 2011 Hong Kong College of Radiologists. | en_US |
dc.language | eng | en_US |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org | en_US |
dc.relation.ispartof | Hong Kong Journal of Radiology | en_US |
dc.subject | Combined Modality Therapy | en_US |
dc.subject | Leukemia | en_US |
dc.subject | Lymph Nodes | en_US |
dc.subject | Lymphoid | en_US |
dc.subject | Rituximab | en_US |
dc.title | Management of chronic lymphocytic leukaemia | en_US |
dc.type | Article | en_US |
dc.identifier.email | Tse, E:ewctse@hku.hk | en_US |
dc.identifier.authority | Tse, E=rp00471 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.scopus | eid_2-s2.0-84860299771 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84860299771&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 14 | en_US |
dc.identifier.issue | 4 SUPPL. | en_US |
dc.identifier.spage | 56 | en_US |
dc.identifier.epage | 62 | en_US |
dc.publisher.place | Hong Kong | en_US |
dc.identifier.scopusauthorid | Tse, E=7005019454 | en_US |
dc.identifier.scopusauthorid | Singh Gill, H=55199478200 | en_US |
dc.identifier.issnl | 2223-6619 | - |